Clarius Mobile Health Corp. received U.S. FDA clearance for the Clarius OB artificial intelligence biometric measurement tool, which is designed to improve access to accurate prenatal monitoring in low-resource regions. The system automatically estimates fetal age, weight and growth intervals critical to assessing fetal health and early identification of potential issues and multiple pregnancies. Read More
A new non-invasive device which enables women to test themselves at home for signs of the cancer-causing human papillomavirus strains in menstrual blood, has been developed with support from the Venture Builder Incubator at the University of Edinburgh. Read More
Nexsen Biotech Pty Ltd. developed a rapid diagnostic test for Group B Streptococcus, a highly prevalent and potentially fatal bacteria that is the single largest maternal health problem faced by pregnant mothers. Read More
The device industry has been clamoring for legislation that would require Medicare coverage for FDA-designated breakthrough devices, a wish that is one step closer to fulfillment as of June 27. Read More
Senescence is a hallmark of aging, and senescent cells have a reputation to match. They are ‘zombie cells,’ sort of dead themselves but alive enough to poison their surroundings through senescence-associated secretory phenotype (SASP). The reality, though, is more complex. Read More
Applaud Medical Inc. continues to file for protection for aspects of its BRIO Enhanced Lithotripsy System, an acoustic enhancer technology which aims to eliminate ureteral stones quickly, affordably, and without the need for general anesthesia or a fluoroscopy procedure that may be conducted in a physician’s office and other non-hospital setting. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: AMS, Bayer, Biotricity, Cepheid, Danaher, Ezra, Nexstim, Peters Surgical, Pleural Dynamics, Qiagen, Rad AI, Rayus, Shineco, Ultrasight, Vivos. Read More
